OZMOSI and Planview have partnered to link external scientific data with internal R&D planning to support pharmaceutical organisations.

This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.

UK Biobank data from all 500,000 participants within the charity’s health database was put up for sale on the Chinese e-commerce website Alibaba.

Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical trials.

Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.